High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease.

Abstract

Wilson's disease (WD) is an inherited disorder of copper metabolism associated with mutations in ATP7B gene. We have shown that the administration of an adeno-associated vector (AAV) encoding a mini version of human ATP7B (VTX-801) provides long-term correction of copper metabolism in a murine WD model. In preparation of a future clinical trial, we have evaluated by positron emission tomography (PET) the value of ⁶⁴Cu biodistribution, excretion pattern, and blood kinetics as pharmacodynamic biomarkers of VTX-801 effects. Six-week-old WD mice were injected intravenously with increasing doses of VTX-801 and 3 weeks or 3 months later with [⁶⁴Cu]CuCl₂. Untreated WD and wild-type (WT) mice were included as controls. Control WD mice showed increased hepatic ⁶⁴Cu retention, reduced fecal excretion of the radiotracer, and altered ⁶⁴Cu blood kinetics (BK) compared with WT mice. VTX-801 treatment in WD mice resulted in a significant reduction of hepatic ⁶⁴Cu accumulation, the restoration of fecal ⁶⁴Cu excretion, and the correction of ⁶⁴Cu BK. This study showed that VTX-801 restores physiological copper metabolism in WD mice, confirming the mechanism of action of VTX-801, and demonstrated the translational potential of [⁶⁴Cu]CuCl₂-PET to explore VTX-801 pharmacodynamics in a minimally invasive and sensitive manner in WD patients.